De novo bronchiectasis in haematological malignancies: patient characteristics, risk factors and survival

Abstract

Bronchiectasis occurs de novo in haematological malignancy and is associated with significant mortality and morbidity. Rituximab predisposes to IgG deficiency and survival time is significantly associated with age, FEV₁ % and stem cell transplantation. http://bit.ly/2KZwCZt.

FIGURE 1

a) Potential aetiology of bronchiectasis in individuals with haematolgoical malignancy. b) Proportion of patients with onset of clinically significant bronchiectasis within 3 years of haematological diagnosis according to haematological diagnosis (n=75). c) Proportion of patients with IgG deficiency according to haematological diagnosis (n=73). d) Kaplan–Meier survival analysis of patients with haematological malignancy from the time of bronchiectasis diagnosis (mean survival time of 3329 days (95% CI 2771–3888 days). Unadjusted hazard ratios (HRs) for e) age (age ≤40 years: HR 0.104 (95% CI 0.02–0.84), p=0.034; age 41–60 years: HR 0.90 (95% CI 0.35–2.24), p=0.804) and f) forced expiratory volume in 1 s (FEV₁) (FEV₁ <40% pred: HR 4.27 (95% CI 1.29–14.09), p=0.017; FEV₁ 41–80% pred: HR 2.12 (95% CI 0.71–6.34), p=0.180). Age-adjusted HRs for g) haematological diagnosis for haematopoietic stem cell transplant (HSCT) (HR 3.94 (95% CI 1.03–15.14), p=0.046) and h) number of lobes affected (HR 2.70 (95% CI 1.00–7.34), p=0.051). pGVHD: pulmonary graft versus host disease; ALL: acute lymphocytic leukaemia; AML: acute myeloid leukaemia; CLL: chronic lymphocytic leukaemia; HL: Hodgkin's lymphoma; MM: multiple myeloma; NHL: non-Hodgkin's lymphoma.